Patents by Inventor Herve Galons
Herve Galons has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230181592Abstract: A compound of formula (I), for use in the treatment of non-traumatic acquired brain injury, in which M represents a NR1R2 group, an OR1 group or a SR1 group, A represents a NR4R5 group, an OR10 group or a hydrogen atom, R3 is a (C1-C6)alkyl group, a (C1-C6)cycloalkyl group, an aryl group, a —CH2-aryl group, a CH2-(C1-C6)cycloalkyl group or a —CH2-heteroaryl group, and its addition salts with pharmaceutically acceptable acids. A compound of formula (I) wherein R5 is a (C1-C8)alkyl group or a (C1-C6)cycloalkyl group, said alkyl and cycloalkyl group being substituted with one, two or three —OCORa group(s).Type: ApplicationFiled: April 23, 2021Publication date: June 15, 2023Applicants: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, WOMEN & INFANTS HOSPITAL OF RHODE ISLAND, SCIENTIAM PHARMAInventors: Aloïse MABONDZO, Anne-Cécile GUYOT, Alain PRUVOST, Narciso COSTA, Hervé GALONS, Nassima OUMATA, Barbara STONESTREET, Clémence DISDIER
-
Patent number: 10561661Abstract: A method for treatment of disease by reduction in macrophages-mediated bacterial killing, including administration to patients in need a compound of formula (I): wherein A is N or CH; B is NO, or S; R1 is H, (C1-C4)alkyl group, methyl(C1-C6)cycloalkyl group or (C1-C6)cycloalkyl group; R2 is an aryl, arylmethyl group or methylheteroaryl group as methylpyridine and methylthiophene; R3 is absent when B is O or S, or is H or (C1-C4)alkyl group when B is N; R4 is (C1-C5)alkyl group or (C1-C4)cycloalkyl group, groups bearing a carboxylic acid group, and (C1-C5)alkyl group or (C1-C4)cycloalkyl substituted by hydroxyl group, halogen group or methoxy group, when B is N, R3 and R4 can together form a 5- or 6-membered heterocycle substituted by carboxylic acid group, substituted by a halogen atom, hydroxyl group, methoxy group or hydroxymethyl group, or pharmaceutically acceptable salt. Also provided are new compounds relating to this use.Type: GrantFiled: February 17, 2015Date of Patent: February 18, 2020Assignees: MANROS THERAPEUTICS, UNIVERSITY OF CHICAGOInventors: Laurent Meijer, Nassima Oumata, Hervé Galons, Aida Gabdoulkhakova, Vladimir Riazanski, Deborah Nelson
-
Publication number: 20150320753Abstract: A method for treatment of disease by reduction in macrophages-mediated bacterial killing, including administration to patients in need a compound of formula (I): wherein A is N or CH; B is NO, or S; R1 is H, (C1-C4)alkyl group, methyl(C1-C6)cycloalkyl group or (C1-C6)cycloalkyl group; R2 is an aryl, arylmethyl group or methylheteroaryl group as methylpyridine and methylthiophene; R3 is absent when B is O or S, or is H or (C1-C4)alkyl group when B is N; R4 is (C1-C5)alkyl group or (C1-C4)cycloalkyl group, groups bearing a carboxylic acid group, and (C1-C5)alkyl group or (C1-C4)cycloalkyl substituted by hydroxyl group, halogen group or methoxy group, when B is N, R3 and R4 can together form a 5- or 6-membered heterocycle substituted by carboxylic acid group, substituted by a halogen atom, hydroxyl group, methoxy group or hydroxymethyl group, or pharmaceutically acceptable salt. Also provided are new compounds relating to this use.Type: ApplicationFiled: February 17, 2015Publication date: November 12, 2015Inventors: Laurent MEIJER, Nassima OUMATA, Hervé GALONS, Aida GABDOULKHAKOVA, Vladimir RIAZANSKI, Deborah NELSON
-
Patent number: 8691982Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof, where R1 is a (C1-C6)alkyl or (C3-C6)cycloalkyl group; R2 is a (C1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkenyl, (C1-C6)fluoroalkyl, (C1-C3)fluoroalkoxy, or (C1-C6)alkoxy(C1-C6)alkyl group, substituted: (i) with one to three hydroxyl groups, or (ii) with an NRaRb group, where Ra and Rb are independently a hydrogen atom or a (C1-C3)alkyl group; or a pyrrolidinylmethyl group substituted with one to three hydroxyl groups; R9 is the same as R2 or hydrogen; the R2 and R9 groups independently being substitutable with an —OCOR3 group, where R3 is a natural or unnatural amino acid derivative or a piperidyl group; alternatively, R2 and R9 together form a heterocyclic compound; X and Y are independently a substitutable phenyl or heteroaryl group, the heteroaryl group being a thienyl, pyridyl, pyrimidinyl, thiazolyl, pyrrolyl, or furanyl group; and R6 is a hydrogen or a (C1-C3)alkyl group.Type: GrantFiled: March 11, 2010Date of Patent: April 8, 2014Assignees: Centre National de la Recherche Scientifique, Universite Paris Descartes, Universite Claude Bernard Lyon 1, Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Laurent Meijer, Hervé Galons, Benoit Joseph, Florence Popowycz, Nassima Oumata
-
Patent number: 8450342Abstract: The invention relates to trisubstituted or tetrasubstituted imidazo[4,5b]pyridines, to their uses as well as to a process for manufacturing them. The compounds of the invention are imidazo[4,5b]pyridines. The first general synthesis of 3,5,7 imidazo[4,5b]pyridines is disclosed in the description. The invention founds application, in particular, in the pharmaceutical field.Type: GrantFiled: February 19, 2010Date of Patent: May 28, 2013Assignees: Centre Nationale de la Recherche Scientifique, Universite de Rennes 1, Universite Paris DescartesInventors: Laurent Meijer, Karima Bettayeb, Herve Galons, Luc Demange, Nassima Oumata
-
Patent number: 8431583Abstract: At least one compound of following formula I: in which: X is C or N, Y is CH3 or OH, and Z is H or CH3, or one of its pharmaceutically acceptable salts, hydrates, esters or isomers, for use in the manufacture of a medicament to treat pathologies in which an imbalance between cell division and apoptosis is involved.Type: GrantFiled: September 12, 2008Date of Patent: April 30, 2013Assignees: Centre National de la Recherche Scientifique, Universite de Rennes 1, Universite Paris Descartes, Universite de Bretagne Occidentale, Centre Hospitalier Universitaire de BrestInventors: Laurent Meijer, Karima Bettayeb, Hervé Galons, Nassima Oumata, Christian Berthou, Karine Lester
-
Publication number: 20120184557Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof, where R1 is a (C1-C6)alkyl or (C3-C6)cycloalkyl group; R2 is a (C1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkenyl, (C1-C6)fluoroalkyl, (C1-C3)fluoroalkoxy, or (C1-C6)alkoxy(C1-C6)alkyl group, substituted: (i) with one to three hydroxyl groups, or (ii) with an NRaRb group, where Ra and Rb are independently a hydrogen atom or a (C1-C3)alkyl group; or a pyrrolidinylmethyl group substituted with one to three hydroxyl groups; R9 is the same as R2 or hydrogen; the R2 and R9 groups independently being substitutable with an —OCOR3 group, where R3 is a natural or unnatural amino acid derivative or a piperidyl group; alternatively, R2 and R9 together form a heterocyclic compound; X and Y are independently a substitutable phenyl or heteroaryl group, the heteroaryl group being a thienyl, pyridyl, pyrimidinyl, thiazolyl, pyrrolyl, or furanyl group; and R6 is a hydrogen or a (C1-C3)alkyl group.Type: ApplicationFiled: March 11, 2010Publication date: July 19, 2012Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE CLAUDE BERNARD LYON 1, UNIVERSITE PARIS DESCARTESInventors: Laurent Meijer, Hervé Galons, Benoit Joseph, Florence Popowycz, Nassima Oumata
-
Publication number: 20100311768Abstract: The invention relates to the use of purine derivatives in the manufacture of a medicament for treating pathological conditions in which an imbalance between cell division and apoptosis is involved, and more particularly in which excessive apoptosis is responsible for the pathological condition. According to the invention, a purine derivative of formula I is used. The invention finds use in the pharmaceutical field.Type: ApplicationFiled: September 12, 2008Publication date: December 9, 2010Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE RENNES 1, UNIVERSITE PARIS DESCARTES, UNIVERSITE DE BRETAGNE OCCIDENTALE, CENTRE HOSPITALIER UNIVERSITAIRE DE BRESTInventors: Laurent Meijer, Karima Bettayeb, Herve Galons, Nassima Oumata, Christian Berthou, Karine Lester
-
Publication number: 20100280065Abstract: The invention relates to trisubstituted or tetrasubstituted imidazo[4,5b]pyridines, to their uses as well as to a process for manufacturing them. The compounds of the invention are imidazo[4,5b]pyridines. The first general synthesis of 3,5,7 imidazo[4,5b]pyridines is disclosed in the description. The invention founds application, in particular, in the pharmaceutical field.Type: ApplicationFiled: February 19, 2010Publication date: November 4, 2010Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE RENNES 1, UNIVERSITE PARIS DESCARTESInventors: Laurent MEIJER, Karima BETTAYEB, Herve GALONS, Luc DEMANGE, Nassima OUMATA
-
New amphetamine derivatives, antibodies against them and pharmaceutical compositions containing them
Publication number: 20030171435Abstract: Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo to amphetamines are disclosed. Methods of preparing the hapten-carrier conjugates and therapeutic compositions are also disclosed. A therapeutic composition containing the hapten-carrier conjugate is useful in the treatment of addiction to amphetamines. Passive immunization using antibodies raised against conjugates of the instant invention also is disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs for treatment of amphetamine abuse.Type: ApplicationFiled: January 23, 2002Publication date: September 11, 2003Applicant: Drug Abuse Sciences, Inc.Inventors: Philippe Pouletty, Jacques Kusmierek, Frederic Koralewski, Herve Galons, Dominique Blanchard, Caroline Gadjou -
Patent number: 6541004Abstract: The ethyl ester of derivatives of benzoyl ecgonine are provided having a linking group at the para position of the benzoyl group. The derivatives are used to bond to immunogenic polypeptides for production of antisera and monoclonal antibodies. The antisera and antibodies find use in assays, for treatment of cocaine overdose and detoxification.Type: GrantFiled: January 4, 2000Date of Patent: April 1, 2003Assignee: DrugAbuse Sciences, Inc.Inventors: Jean-Michel Scherrmann, Philippe Pouletty, Herve Galons
-
Publication number: 20020102659Abstract: The ethyl ester of derivatives of benzoyl ecgonine are provided having a linking group at the para position of the benzoyl group. The derivatives are used to bond to immunogenic polypeptides for production of antisera and monoclonal antibodies. The antisera and antibodies find use in assays, for treatment of cocaine overdose and detoxification.Type: ApplicationFiled: January 9, 2002Publication date: August 1, 2002Inventors: Jean-Michel Scherrmann, Philippe Pouletty, Herve Galons
-
Patent number: 6114508Abstract: The ethyl ester of derivatives of benzoyl ecgonine are provided having a linking group at the para position of the benzoyl group. The derivatives are used to bond to immunogenic polypeptides for production of antisera and monoclonal antibodies. The antisera and antibodies find use in assays, for treatment of cocaine overdose and detoxification.Type: GrantFiled: August 25, 1998Date of Patent: September 5, 2000Assignee: DrugAbuse Sciences, Inc.Inventors: Jean-Michel Scherrmann, Philippe Pouletty, Herve Galons
-
Patent number: 5817770Abstract: The ethyl ester of derivatives of benzoyl ecgonine are provided having a linking group at the para position of the benzoyl group. The derivatives are used to bond to immunogenic polypeptides for production of antisera and monoclonal antibodies. The antisera and antibodies find use in assays, for treatment of cocaine overdose and detoxification.Type: GrantFiled: March 21, 1997Date of Patent: October 6, 1998Assignee: Drug Abuse Sciences, Inc.Inventors: Jean-Michel Scherrmann, Philippe Pouletty, Herve Galons
-
Patent number: 5631244Abstract: Mono (6-amino-6-deoxy)cyclodextrin derivatives substituted in the 6-position by an .alpha.-amino acid residue. These derivatives correspond to the following general formula: ##STR1## in which: CD represents .alpha.-, .beta.- or .gamma.-cyclodextrin,n is 0 or 1, andZ represents a divalent radical chosen from:(i) --CH.sub.2(ii) --O--CH.sub.2--(iii) --S--CH.sub.2 --, ##STR2## and (v) --O--C.sub.6 H.sub.4 --CH.sub.2 --.These derivatives find an application in the formation of inclusion complexes of active substances and can be used in various fields, in particular in cosmetics, in dermatology and in pharmacology.Type: GrantFiled: May 13, 1994Date of Patent: May 20, 1997Assignee: L'OrealInventors: Herve Galons, Jean Maignan, Jallal Gnaim